Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

566P - Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: A post-hoc analysis of the CinClare study

Date

14 Sep 2024

Session

Poster session 16

Topics

Clinical Research;  Radiation Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Ji Zhu

Citation

Annals of Oncology (2024) 35 (suppl_2): S428-S481. 10.1016/annonc/annonc1588

Authors

J. Zhu1, Y. Wang1, A. Liu2, X. Sun3, L. Liu1, T. Zhang4, Y. Zhu5, Z. Zhang6

Author affiliations

  • 1 Radiation Oncology Dept., Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 2 Radiation Oncology, The Second Affiliated Hospital of Nanchang University, 330000 - Nanchang/CN
  • 3 Radiation Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 210039 - Nanjing/CN
  • 4 Internal Medicine-oncology, The First Affiliated Hospital of Chongqing Medical University, 400016 - Chongqing/CN
  • 5 Radiation Oncology, Second Affiliated Hospital of Soochow University, 000000 - Soochow/CN
  • 6 Radiation Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 566P

Background

The CinClare phase III study (NCT02605265) demonstrated that the addition of irinotecan to capecitabine in combination with radiotherapy significantly increased the pathologic complete response(pCR) rate in locally advanced rectal cancer (LARC). However, it was not well tolerated among some patients, who failed to complete their planned weekly irinotecan chemotherapy. This study is a post-hoc analysis of the CinClare study designed to assess the impact of irinotecan chemotherapy completion in preoperative chemoradiotherapy on efficacy, toxicity, and long-term survival.

Methods

Patients were categorized into three groups based on the cycles of weekly irinotecan they actually received in the CinClare study. Group A received only capecitabine, while Group B and C actually received 1-3 or 4-5 cycles of weekly irinotecan during the course of chemoradiotherapy, respectively. Tumor response, toxicity, and long-term survival were compared among the three groups.

Results

A total of 356 patients were included in the analysis. The pCR rates were 17.4%, 20.8%, and 38.4% in Groups A, B, and C, respectively (P < 0.001). Grade 3-4 adverse events were 6.2%,52.8%,32.0% respectively. The 5-year DFS and OS rates in Groups A, B, and C were 70.6% vs. 76.9% vs. 78.1% and 76.1% vs. 80.0% vs. 84.2%, respectively.

Conclusions

The administration of 4-5 cycles of weekly irinotecan in preoperative chemoradiotherapy was significantly associated with better tumor response and showed a trend toward beneficial DFS and OS in patients with LARC.

Clinical trial identification

NCT02605265.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.